Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model

Lung Cancer

Volumn 42, Issue 3, 2003, Pages 335-344

  Liu, Jiang ^a   Tsao, Ming S ^b   Pagura, Marco ^a   Shalinsky, David R ^c   Khoka, Rama ^a   Fata, Jim ^a   Johnston, Michael R ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

AG3340; Chemotherapy; H460 orthotopic lung cancer model; Matrix metalloproteinase (MMP); MMP inhibitor (MMPI); Prinomastat

Indexed keywords

CARBOPLATIN; GELATINASE A; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER MODEL; CANCER SURVIVAL; CONTROLLED STUDY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; KIDNEY METASTASIS; LUNG CARCINOMA; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT;

EID: 0344982795     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00355-6     Document Type: Article

References (26)

1. Anderson I.C., Shipp M.A., Docherty A.J.P.et al. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res. 56:1996;715-718.
2. Levy D., Ezrin A. Matrix metalloproteinase inhibitor drugs. Expert Opin Emerg Drugs. 2:1997;1.
3. Wojtowicz-Praga S.M., Dickson R.B., Hawkins M.J. Matrix metalloproteinase inhibitors. Invest. New Drugs. 15:1997;61-75.
4. Brown P.D. Matrix metalloproteinase inhibitors in the treatment of cancer. Med. Oncol. 14:1997;1-10.
5. Nelson J.S., Wright W.H., Berns M.W. Comparison of fluorescence and photodynamic activities of whole hematoporphyrin derivative and its enriched active components. J. Natl. Cancer Inst. 75:1985;1135-1140.
6. Shalinsky D.R., Brekken J., Zou H.et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann. N. Y. Acad. Sci. 878:1999;236-270.
7. Tokuraku M., Sato H., Murakami S.et al. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int. J. Cancer. 64:1995;355-359.
8. Itoh T., Tanioka M., Yoshida H.et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58:1998;1048-1051.
9. Sato H., Takino T., Okada Y.et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 370:1994;61-65.
10. Strongin A.Y., Collier I., Bannikov G.et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 270:1995;5331-5338.
11. Momiki S., Baba M., Caamano J.et al. In vivo and in vitro invasiveness of human lung carcinoma cell lines. Invasion Metastasis. 11:1991;66-75.
12. Garbisa S., Scagliotti G., Masiero L.et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res. 52:1992;4548-4549.
13. Wang X., Fu X., Brown P.D.et al. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 54:1994;4726-4728.
14. Chirivi R.G., Garofalo A., Crimmin M.J.et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int. J. Cancer. 58:1994;460-464.
15. An Z., Wang X., Willmott N.et al. Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin. Exp. Metastasis. 15:1997;184-195.
16. Santos O., McDermott C.D., Daniels R.G., Appelt K. Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin. Exp. Metastasis. 15:1997;499-508.
17. Howard R.B., Mullen J.B., Pagura M.E., Johnston M.R. Characterization of a highly metastatic, orthotopic lung cancer model in the nude rat. Clin. Exp. Metastasis. 17:1999;157-162.
18. Howard R.B., Chu H., Zeligman B.E.et al. Irradiated nude rat model for orthotopic human lung cancers. Cancer Res. 51:1991;3274-3280.
19. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
20. Johnston M.R., Mullen J.B., Pagura M.E., Howard R.B. Validation of an orthotopic model of human lung cancer with regional and systemic metastases. Ann. Thorac. Surg. 71:2001;1120-1125.
21. Thomas P., Khokha R., Shepherd F.A.et al. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J. Pathol. 190:2000;150-156.
22. Li R., Huang L., Guo H., Toole B.P. Basigin (murine EMMPRIN) stimulates matrix metalloproteinase production by fibroblasts. J. Cell Physiol. 186:2001;371-379.
23. Price A., Shi Q., Morris D.et al. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin. Cancer Res. 5:1999;845-854.
24. Shalinsky D.R., Brekken J., Zou H.et al. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Clin. Cancer Res. 5:1999;1905-1917.
25. Smylie M, et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC). In: Proceedings of the ASCO 20, no. 1226, 2001.
26. Sledge G.W. Jr., Qulali M., Goulet R.et al. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J. Natl. Cancer Inst. 87:1995;1546-1550.